@article{oai:repo.qst.go.jp:00044084,
 author = {Watanabe, Naoyuki and Endou, Keigo and Tanada, Shuji and Murata, Hajime and Sasaki, Yasuhito and et.al and 渡辺 直行 and 遠藤 啓吾 and 棚田 修二 and 村田 啓 and 佐々木 康人},
 issue = {2},
 journal = {Nuclear Medicine and Biology},
 month = {},
 note = {Novel yttrium-90 (90Y)-labeled phosphorothioate antisense oligonucleotides were designed as a potential targeted radionuclede therapeutic agent for malignant tumors.  A 15-mer phosphorothioate antisense oligonucleotide, which was complementary to the translation start region of the N-myc oncogene mRNA, was conjugated with isothiocyanobenzyl ethylenediamine tetraacetic acid (SCN-Bn-EDTA), via a C-5-substituted deoxyuridine that had replaced a thymine in the oligonucleotide, and wa then labeled with 90Y-acetate. Following purification, the radiochemical purity of hte 90Y-Bn-EDTA-phosphorothioate antisence oligonucleotides was estimated by 2.0% agarose gel electrophoresis, and the specific hybridization of 90Y-Bn-EDTA-phosphorothioate antisense oligonucleotide to a phosphorodiester sense oligonucleotide was investigated by 20% polyacrylamide gel electrophoresis in a cell-free system. Radiochemical purity was 98.7   0.4% at 72 h after labeling and 90.3   0.9% after 72-h incubation with human normal serum.  The 90Y-Bn-EDTA-phosphorothioate antisense oligonucleotide hybridized specifically to a complementary phosphorodiester sense oligonucleotide.  In conclusion, phosphorothioate antisense oligonucleotides can be labeled stably with 90Y using SCN-Bn-EDTA without loss of hybridization properties.},
 pages = {239--243},
 title = {Labeling of Phosphorothioate Antisense Oligonucleotides with Yttrium-90},
 volume = {26},
 year = {1999}
}